Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 4/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3407088 | 0.91 | FFAR4 (0.50) | THRATHRBPTGDRFFAR4HRH1 | |
| SCHEMBL3402981 | 0.83 | THRA (0.58) | THRATHRBPTGDRNPSR1PTGER1 | |
| SCHEMBL3813636 | 0.83 | PTGDR (0.57) | THRATHRBPTGDRFFAR4 | |
| SCHEMBL3402978 | 0.81 | THRA (0.48) | THRATHRBPTGDRPTGER1PTGER4 | |
| SCHEMBL23881846 | 0.81 | CARM1 (0.49) | HRH1CARM1PRMT1 | |
| SCHEMBL6063960 | 0.80 | THRA (0.50) | THRATHRBFFAR4PTGER1PTGER4 | |
| SCHEMBL23881748 | 0.80 | CARM1 (0.51) | HRH1CARM1PRMT1 | |
| SCHEMBL3407137 | 0.79 | THRA (0.46) | THRATHRBPTGDRPTGER1PTGER4 | |
| SCHEMBL23881824 | 0.79 | THRA (0.41) | THRATHRBPTGDRFFAR4HRH1 | |
| SCHEMBL6063195 | 0.79 | THRA (0.52) | THRATHRBFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487121-B2 | Chromane derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-07-16 | — | — | US | disclosed |
| CN-103183660-A | Chromane derivative used as TRPV3 (transient receptor potential vanilloid 3) conditioning agent | GLENMARK PHARMACEUTICALS SA | 2013-07-03 | — | — | CN | disclosed |
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2010-12-09 | — | — | US | disclosed |
| EP-2254879-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | Glenmark Pharmaceuticals S.A. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009084034-A2 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S. A. (CH) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311778-A1 | CHROMANE DERIVATIVES AS TRPV3 MODULATORS | TRPV3, TRPV2, TRPV1 | THRA 530/4885THRB 662/4885PTGDR 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.